However, these results provide clues about the role of FGF-21 as a key regulator of hepatic lipid metabolism in humans and suggest that serum FGF-21 can be used as a biomarker for NASH. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.